IV Double and Triple Concentrated Nicardipine for Stroke and ICH
Unknown status
PDL BioPharma, Inc.
Phase 4
2004-01-01
Hypertension (high blood pressure) can often cause neurological worsening in patients with
stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of
nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of
Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The
purpose of this study is to evaluate safety and efficacy of double or triple concentrated
peripheral intravenous (IV) Nicardipine.
IV Double and Triple Concentrated Nicardipine for Stroke and ICH
Unknown status
OSF Healthcare System
Phase 4
2004-01-01
Hypertension (high blood pressure) can often cause neurological worsening in patients with
stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of
nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of
Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The
purpose of this study is to evaluate safety and efficacy of double or triple concentrated
peripheral intravenous (IV) Nicardipine.
Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department
Completed
EKR Therapeutics, Inc
Phase 4
2008-10-01
The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol
administered intravenously for the management of hypertension in the emergency department
setting.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
